Three-Drug Combination Regimen in Pancreatic Cancer Treatment: Are We There Yet?

Soonmo Peter Kang; Muhammad Wasif Saif

doi:10.6092/1590-8577/3327

Soonmo Peter Kang Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA
Muhammad Wasif Saif Columbia University College of Physicians and Surgeons & New York Presbyterian Hospital. New York, NY, USA

DOI: https://doi.org/10.6092/1590-8577/3327

Keywords: Drug Therapy, Palliative Care, Pancreatic Neoplasms

Abstract

No abstract available.

Image: Herbert Irving Cancer Center. New York, NY, USA

Downloads

Download data is not yet available.

References

Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin (LV), irinotecan (I), and oxaliplatin (O)) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28(15 Suppl.):Abstract 4010.

Conroy T, Paillot B, Francois E, Deplanque G, Bugat R, Jacob JH, et al. Final results of folfirinox: A triple combination of 5-FU/leucovorin (5-FU/LV), irinotecan (I) and oxaliplatin (O)) as first-line chemotherapy in advanced pancreatic adenocarcinoma (APA). Proc Am Soc Clin Oncol 2003; 22:Abstract 1045.

Ychou M, Desseigne F, Guimbaud R, Ducreux M, Bouché O, Bécouarn Y, et al. Randomized phase II trial comparing folfirinox (5FU/leucovorin (LV), irinotecan (I) and oxaliplatin (O)) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. J Clin Oncol 2007; 25(18 Suppl.):Abstract 4516.

Vervenne W, Bennouna J, Humblet Y, Gill S, Moore MJ, Van Laethem J, et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2008; 26(15 Suppl.):Abstract 4507.

Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008; 61:167-75. [PMID 17440727]

Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, et al. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol 2009; 27(15 Suppl.):Abstract 4623.

Burtness BA, Powell ME, Berlin JD, Liles KD, Chapman AE, Mitchell EP, Benson AB. Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19-9 results. J Clin Oncol 2008; 26(15 Suppl.):Abstract 4642.

Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001; 19:2679-86. [PMID 11352960]

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6:488-95. [PMID 11743211]

Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658-63. [PMID 19826418]

Sharma MR, Maitland ML, Ratain MJ. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J 2009; 15:426-30. [PMID 19826363]

Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281:1589-91. [PMID 7004559]

Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882-5. [PMID 8044610]

Kindler HL, Bylow KA, Hochster HS, Friberg G, Micetich K, Locker G, et al. A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. J Clin Oncol 2006; 24(18 Suppl.):Abstract 4040.

Kullmann F, Hollerbach S, Dollinger M, Harder J, Fuchs M, Messmann H, et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study. Proc ASCO Gastrointestinal Cancers Symposium 2007:Abstract 128.

Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, et al. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother 2008; 20:119-25. [PMID 18343754]

Garnier C, Rebischung C, Chirpaz E, Balosso J, Fournet J, Pasquier D, et al. Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine and oxaliplatin (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 2001; 20:Abstract 620.

Oh D, Lee K, Lee K, Sohn C, Park Y, Zang D, et al. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. J Clin Oncol 2009; 27(15 Suppl.):Abstract 4607.

Kozuch P, Areneo M, Homel P, Robin A, Firoozi K, Mortazavi F, et al. Biweekly sequential gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin), and cisplatin (GFP): a highly active novel combination for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc Am Soc Clin Oncol 2001; 20:Abstract 617.

Lubner SJ, Schelman WR, Mulkerin D, Holen KD, Seo S, LoConte NK. Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl.):Abstract 4143.

Reni M, Panucci MG, Passoni P, Bonetto E, Nicoletti R, Ronzoni M, et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 2004; 22:688-96. [PMID 15581049]